In conclusion we have shown that E2 deprivation with an LH-RH analogue, followed by tailored chemotherapy, radiation therapy and hormonal therapy in ER+ tumours, decreased plasma VEGF and T-Regs in premenopausal high-risk ER+ and ER− BC patients. The gene discussed is GNRH1; the disease is neoplasm.